Revised forecast
Fiscal year ending October 2026 · Full yearPrevious forecast published Announced 11 December 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
As the Company merged by absorption with its wholly owned subsidiary ハイブリッドメディカル株式会社 effective 1 July 2026, it no longer had any consolidated subsidiaries and therefore transitioned to non-consolidated financial reporting. The standalone earnings forecast was calculated by restructuring the consolidated earnings forecast announced on 11 December 2025 on a standalone basis and is currently under review.
| Item | Details |
|---|---|
| Net Sales | ¥3,418 million → ¥3,320 million |
| Operating profit | ¥-170 million → ¥-221 million |
| Ordinary income | ¥-164 million → ¥-210 million |
| Profit attributable to owners of the parent | ¥-136 million → ¥-107 million |
| Net income per share | -6.90 yen and sen → -5.41 yen and sen |
| Fiscal Period Covered | Fiscal year ending October 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | Announced 11 December 2025 |
| Previous-period results | Standalone results for the previous fiscal year (fiscal year ended October 2025): net sales of ¥3,602 million, operating profit of ¥115 million, ordinary profit of ¥122 million, net loss of ¥18 million, and net loss per share of ¥0.95. Consolidated results for the previous fiscal year (fiscal year ended October 2025): net sales of ¥3,711 million, operating profit of ¥166 million, ordinary profit of ¥167 million, net income attributable to owners of the parent of ¥10 million, and net income per share of ¥0.54. |
| Reason for the revision | As the Company merged by absorption with its wholly owned subsidiary ハイブリッドメディカル株式会社 effective 1 July 2026, it no longer had any consolidated subsidiaries and therefore transitioned to non-consolidated financial reporting. The standalone earnings forecast was calculated by restructuring the consolidated earnings forecast announced on 11 December 2025 on a standalone basis and is currently under review. |
| Consolidated / non-consolidated | Non-consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.As the Company merged by absorption with its wholly owned subsidiary ハイブリッドメディカル株式会社 effective 1 July 2026, it no longer had any consolidated subsidiaries and therefore transitioned to non-consolidated financial reporting. The standalone earnings forecast was calculated by restructuring the previously announced consolidated earnings forecast on a standalone basis and is currently under review.